The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.
NEW YORK (GenomeWeb) – The Foundation for Innovative New Diagnostics is collaborating with multiple firms to accelerate the development of low-cost molecular diagnostics for tuberculosis and drug resistance determination, the non-profit organization said today.
NEW YORK (GenomeWeb) – QuantuMDx, a Newcastle, UK-based molecular diagnostics company, last week announced that it had successfully completed the development of its Q-POC handheld testing device.
